INTERACT-EUROPE 100

                                                        

About the Project

Cancer patients in Europe are treated by an array of different specialties and professions: medical oncologists, radiation oncologists, surgical oncologists, cancer nurses and many others. Teamwork is essential. But high functioning teamwork requires a clear understanding of each other’s roles and competencies. 

INTERACT-EUROPE 100 is an ambitious project to provide cancer care professionals with the training necessary to enhance this collaboration – now coming to 100 cancer centres across Europe.

INTERACT-EUROPE 100 aims to implement the Inter-specialty Cancer Training (ISCT) curriculum developed under its predecessor, the INTERACT-EUROPE project. The training curriculum is available online here.

 

INTERACT-EUROPE 100 is a 36-month project (December 2023 – December 2026). It is co-funded by the European Union under the EU4Health programme 2021-2027 as part of Europe’s Beating Cancer Plan.

This project involves 38 partner organisations from 15 European countries implementing this novel training curriculum.

For more information, please check out the INTERACT-EUROPE 100 webpage.

Project Goal

The goal of INTERACT- EUROPE  100 is to provide cancer care professionals with the training necessary to enhance a collaboration with 100 cancer centres across Europe

INTERACT-EUROPE 100 embraces the values of patient-centricity and inclusivity and aims at making a lasting contributing to improved cancer patient outcomes and patient care across Europe.

Project Objectives

The objective of the ISCT programme is to foster a patient-centric approach to quality cancer care through the promotion of multidisciplinary and multi-professional teams working across Europe.

SIOP Europe's Role in the Project

The European Society for Paediatric Oncology (SIOP Europe) is responsible for Task 2.5, within Work Package 2 : “Development of add-on  module: Review and adaptation of the inter-speciality cancer training programme  for paediatric oncology”.